Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab in Chronic Pulmonary Sarcoidosis
2024-511115-25-00Phase 2Completed
- Sponsor
- Kinevant Sciences
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in Chronic Pulmonary Sarcoidosis comparing Namilumab with Placebo (2 arms). Started Mar 2024; status: completed.
02
Drugs
namilumab
03
Conditions
Chronic Pulmonary Sarcoidosis
Beyond the preview
Go deeper on 2024-511115-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511115-25-00.